The European Medicines Agency (EMA) approved on Friday the use of the Modern Covid vaccine for young people aged 12 to 17, which becomes the second authorized vaccine for adolescents in the 27 countries of the European Union.
The European Medicines Agency (EMA) said on Friday that it had given the green light to also recommend Moderna’s vaccine against Covid-19 for children aged 12 to 17. Currently, this vaccine called “Spikevax” is already authorized for 18 years and more throughout the European Union. The administration of the vaccine for children aged 12 to 17 years will be the same as for people aged 18 and over: two injections into the muscles of the upper arm, separated by four weeks.
Following clinical studies on the use of this product in young adolescents, the European agency considered it safe and effective to authorize it for this age group.
Study on 3,732 children
The effects of Spikevax, of the American biotechnology company Modern, were studied in a study with 3,732 children aged 12 to 17 years. This study showed that serum produced an antibody response comparable in young people aged 12 to 17 years to that observed in young adults aged 18 to 25 years. “These results allowed the EMA Human Medicines Committee (CHMP) to conclude that the efficacy of Spikevax in children aged 12 to 17 years is similar to that in adults.The Amsterdam-based agency concluded that the most common side effects are also the same as those seen in adults.
The Pfizer / BioNTech alliance vaccine, which used the same messenger RNA technology as the Modern vaccine, had already been licensed at the age of twelve in the United States, Canada, and the 27 countries of the European Union.
Currently, four vaccines against Covid-19 are authorized at European level: those of AstraZeneca (Vaxzevria), Moderna (Spikevax), Janssen and BioNTech-Pfizer (Comirnaty). The latter is already authorized from the age of 12 and until now was the only one within the European Union.
Half of adults in Europe, or 200 million people, are vaccinated against Covid-19, the European Commission said on Thursday.